Oxford Finance Announces Closing of $75 Million Credit Facility with Fusion Pharmaceuticals

ALEXANDRIA, Virginia and HAMILTON, Ontario–(BUSINESS WIRE)–Oxford Finance LLC (“Oxford”), a leading specialty finance firm providing preferred debt securities to life sciences and healthcare companies worldwide, announces the closing of a loan $75 million senior secured term with Fusion Pharmaceuticals Inc. (NASDAQ: FUSN) (“Fusion” or “the Company”), a clinical-stage oncology company focused on the development of next-generation radiopharmaceuticals in as precision drugs to treat a wide range of cancers.

Proceeds from the transaction will be used for general working capital and to fund the advancement of the Company’s pipeline.

Fusion Pharmaceuticals is leveraging its expertise and Targeted Alpha Therapy (“TAT”) platform to advance a portfolio of alpha-emitting radiopharmaceuticals utilizing diverse classes of targeting molecules to pursue cancer targets in areas of unmet medical need are high.

“The Company’s TAT ​​platform has the potential to enhance the tumor-killing power of radiation and is designed for broader applicability across multiple tumor types,” said Christopher A. Herr, Senior Managing Director of Oxford. “We are pleased to partner with Fusion and support its diverse pipeline focused on addressing unmet cancer treatment needs.”

About Oxford Finance LLC

Oxford Finance is a specialist finance company that provides senior secured loans to public and private life sciences and healthcare companies worldwide. For over 20 years, Oxford has provided flexible financing solutions to its clients, enabling these businesses to maximize their equity by leveraging their assets. Since 2002, Oxford has issued approximately $8.8 billion in loans. Oxford is headquartered in Alexandria, Virginia, with additional offices in California (San Diego, Palo Alto, and Los Angeles) and the major metropolitan areas of Boston and New York. For more information, visit https://oxfordfinance.com.

About Fusion Pharmaceuticals, Inc.

Fusion Pharmaceuticals is a clinical-stage oncology company focused on the development of next-generation radiopharmaceuticals as precision medicines. Fusion links alpha particle-emitting isotopes to various targeting molecules to selectively deliver alpha-emitting payloads to tumors. Fusion’s lead program, FPI-1434 targeting the insulin-like growth factor receptor 1, is currently in a Phase 1 clinical trial. The pipeline includes FPI-1966, targeting the insulin-like growth factor receptor 3 Fibroblast Growth Factor (FGFR3), moving to a Phase 1 study following recent Investigational New Drug (IND) approval; and FPI-2059, a small molecule targeting neurotensin receptor 1 (NTSR1). In addition to a robust proprietary pipeline, Fusion is collaborating with AstraZeneca to co-develop novel targeted alpha therapies (TATs) and combination programs between Fusion’s TATs and DNA damage repair inhibitors (DDRis) d ‘AstraZeneca and immuno-oncology agents. Fusion has also entered into a collaboration with Merck to evaluate FPI-1434 in combination with Merck’s KEYTRUDA® (pembrolizumab) in patients with IGF-1R-expressing solid tumors. Fusion and Hamilton, Ontario-based McMaster University are constructing a current Good Manufacturing Practices (GMP)-compliant radiopharmaceutical manufacturing facility designed to support the manufacturing of the company’s growing TAT pipeline.

About Sharon Joseph

Check Also

Apply for a car loan? It’s complicated right now

Auto credit rose for a second consecutive month in October, but the news was not …